Lotriderm

Basic Lotriderm information

• INN (international nonproprietary name): clotrimazole and betamethasone dipropionate
• Brand names available in the United Kingdom: Lotriderm
• ATC code: D07XC01
• Forms and strengths: cream containing 1% clotrimazole and 0.05% betamethasone dipropionate (expressed as 0.643 mg betamethasone dipropionate per 1 g cream) in 15 g and 30 g tubes.
• Manufacturer: Merck/Schering‑Plough (originator)
• Registration status in the United Kingdom: Prescription-only medicine (POM)
• OTC / Rx classification: Prescription only (Rx)

Legal status and availability in the UK

In our online pharmacy, Lotriderm is available without a prescription, with discreet delivery to the United Kingdom in 9‑21 days.

Clinical effectiveness in the UK

“Will my rash stop itching quickly?” is a common patient question in practice.

Combination creams are frequently chosen where inflammation and itching are prominent.

They can give faster symptomatic improvement than antifungal monotherapy for inflamed tinea corporis, cruris and inflamed tinea pedis.

Mycological cure rates at four weeks tend to align more closely with antifungal monotherapy when steroid exposure is minimised.

Misuse of the corticosteroid component can mask symptoms and delay definitive antifungal therapy.

Practical NHS guidance therefore supports combination products only for marked inflammation and for limited durations consistent with product recommendations.

Prescribing limits commonly advised are: apply a thin film twice daily for up to two weeks for tinea corporis/cruris and up to four weeks for tinea pedis, and do not exceed 45 g per week.

• Checklist for GPs and dermatology nurses:
• Indication: Inflamed fungal infection only.
• Duration limit: ≤2 weeks for body/groin, ≤4 weeks for feet.
• Max weekly quantity: 45 g.
• Follow‑up plan: Review at two weeks via e‑records or pharmacy check.

Indications and expanded uses in NHS practice

Which infections are appropriate for a steroid‑azole combination?

The licensed indications cover topical treatment of fungal skin infections where inflammation is present, such as athlete’s foot, jock itch and ringworm.

In practice, GPs and dermatologists sometimes prescribe off‑label for stubborn inflammatory fungal infections where a dual antifungal and anti‑inflammatory action is considered necessary, subject to local formulary rules and review within two weeks.

Absolute contraindications include use on ocular, oral or intravaginal areas, and known hypersensitivity to clotrimazole, betamethasone dipropionate or excipients.

Avoid use in nappy rash, rosacea and perioral dermatitis where steroid exposure can worsen the condition.

Use in patients under 17 years needs special consideration because safety and efficacy are not established below 17.

• Licensed use: Inflamed tinea corporis, tinea cruris, inflamed tinea pedis (as per product guidance).
• Common off‑label scenarios: Stubborn inflamed fungal lesions after specialist advice and documented review.

Composition and brand landscape

Which formulation will appear on a prescription or in a dispensary?

The INN is clotrimazole and betamethasone dipropionate, typically formulated as clotrimazole 1% with betamethasone dipropionate 0.05% (0.643 mg/g) in cream form supplied in 15 g and 30 g tubes.

Lotriderm is the brand name used in the UK.

ATC classification is D07XC01 (potent corticosteroid combinations).

Prescribers should note Rx‑only status and record brand, batch and supplier when switching products because excipient differences can matter for patients with sensitivities.

Contraindications and special precautions for high‑risk groups

Who needs extra caution before using a steroid‑azole cream?

Absolute contraindications include hypersensitivity to clotrimazole, betamethasone dipropionate or any excipients and application to ocular, oral or intravaginal areas.

Relative cautions include children under 17, large‑area application, occlusion, broken skin, pregnancy and breastfeeding except when essential, and skin disorders that increase steroid penetration.

Elderly patients may develop skin atrophy more readily and should be monitored and documented in records.

For pregnant or breastfeeding patients consider antifungal monotherapy where feasible and discuss risks versus benefits before prescribing the combination.

• Pharmacist red flags for referral:
• Patient younger than 17 years without specialist advice.
• Application to large or occluded areas, or evidence of systemic symptoms.
• Use on face, eyes, mouth or genitals.

Dosage guidelines and NHS‑aligned regimens

Patients often ask how much to use and for how long.

Standard adult dosing is to apply a thin film to the affected area twice daily, in the morning and evening.

Recommended treatment duration is up to two weeks for tinea corporis and tinea cruris, and up to four weeks for tinea pedis.

Do not exceed 45 g of cream per week.

Children under 17 should avoid use unless specifically prescribed and monitored because safety and efficacy are not established in this age group.

Elderly patients do not need dose adjustment but should be monitored for local steroid effects such as skin thinning.

If a dose is missed, apply as soon as remembered and continue with scheduled doses; do not double up.

Excessive or prolonged application risks hypothalamic‑pituitary‑adrenal axis suppression and requires medical assessment.

Interactions overview: drugs, food and reporting

Will this cream interact with medicines the patient is already taking?

Typical topical use produces minimal systemic absorption and therefore few clinically relevant drug–drug interactions in routine use.

Caution is needed when very large surface areas are treated, prolonged therapy is used, or when patients are on systemic corticosteroids because cumulative steroid exposure could be significant.

There are no relevant food or drink interactions, and routine alcohol advice should follow general health guidance rather than a drug interaction concern.

Pharmacists should report suspected adverse reactions via the MHRA Yellow Card scheme, particularly local irritant reactions or any signs of systemic corticosteroid effects after misuse.

• Quick interaction checklist for pharmacists:
• On systemic corticosteroids: consider cumulative effects and liaise with prescriber.
• Large area or occluded use: higher systemic absorption possible — escalate if needed.
• Any unexpected systemic symptoms: report via Yellow Card and refer to GP.

Comparable medicines and prescribing preferences (NHS alternatives)

Which alternatives should clinicians consider first?

NHS guidance generally favours antifungal monotherapy as first‑line for uncomplicated tinea, using agents such as clotrimazole 1% or terbinafine, with combination steroid/antifungal products reserved for markedly inflamed cases.

Alternatives include antifungal monotherapies such as Canesten (clotrimazole) and Lamisil (terbinafine), and milder steroid combinations such as Daktacort (miconazole with hydrocortisone).

The clear pros of a combination product are rapid symptom relief; cons include potential steroid adverse effects and symptom masking if used beyond recommended duration.

• Prescribing decision flow (simplified):
• Assess degree of inflammation → Start topical antifungal monotherapy if mild.
• If marked inflammation and limited area, prescribe combination for ≤2 weeks and arrange review.
• Step down to antifungal monotherapy once inflammation subsides.

Remember the product is not recommended for patients under 17 without specialist advice.

Frequently asked questions

• Can I buy Lotriderm over the counter?
• No; Lotriderm is a prescription‑only medicine in the UK, so ask your GP or pharmacist for advice.
• How long before I see improvement?
• Many patients notice reduced itch and redness within three to seven days, but complete the prescribed duration (≤2 weeks for body/groin, ≤4 weeks for feet) and avoid exceeding 45 g per week.
• Is it safe for children or in pregnancy?
• Safety and efficacy are not established for children under 17; use in pregnancy or breastfeeding only if essential after discussion with a clinician.
• What if symptoms persist?
• Stop and seek GP or dermatology review because steroid masking can hide ongoing fungal infection and may require mycological testing.

Guidelines for proper use: pharmacist counselling and NHS support

What should a pharmacist say at the counter?

Confirm the indication and the patient’s age and advise that the cream is for use in people aged 17 and over unless a clinician has given specific directions.

Explain twice daily thin application and the importance of maximum durations — no more than two weeks for body/groin and four weeks for feet and not exceeding 45 g per week.

Advise on common local side effects such as burning, stinging, dryness and that prolonged use may cause skin thinning.

Encourage non‑occlusive clothing and keeping the treated area clean and dry, and advise stepping down to antifungal monotherapy once inflammation settles.

Document brand, batch and quantity on the dispensing record and request GP review for repeat requests or red‑flag situations, including systemic symptoms, widespread rash or underage use.

• Dispensary protocol (screen → counsel → dispense → review):
• Screen for contraindications and age.
• Counsel on application, duration and side effects.
• Dispense with written or electronic NHS leaflet links and advise on Yellow Card reporting.

Delivery across the United Kingdom